NEW CASES

FULLY
EQUIPPED

Shareholder Class Action Filed Against Lion Biotechnologies, Inc.

Notice is hereby given that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Lion Biotechnologies, Inc. (“Lion Biotechnologies”) (Nasdaq: LBIO) securities between November 14, 2013 and April 10, 2017, inclusive (the “Class Period”).

Lion Biotechnologies investors may receive additional information about the case by clicking the link "Join this Class Action" above. 


According to the complaint, Lion Biotechnologies is a clinical-stage biotechnology company that focuses on developing and commercializing cancer immunotherapy products.

The Class Period commences on November 14, 2013, when Lion Biotechnologies filed a Form 10-Q with the SEC to discuss the Company’s third quarter 2013 financial and operational results. 

According to the complaint, on May 14, 2014, Lion Biotechnologies disclosed that it had previously received a subpoena from the SEC, stating in pertinent part: “On April 23, 2014, the Company received a subpoena from the Securities Exchange Commission (the “SEC”) that stated that the staff of the SEC is conducting an investigation In the Matter of Galena Biopharma, Inc. File No. HO 12356 and that the subpoena was issued to the Company as part of the foregoing investigation.”

On April 10, 2017, the SEC found that, between “September 2013 to March 2014, Lion, through its former Chief Executive Officer, Manish Singh, engaged in a scheme to mislead investors by commissioning over 10 internet publications and 20 widely distributed emails promoting Lion to potential investors that purported to be independent from the company when, in fact, they were paid promotions. Singh engaged Lidingo Holdings, a stock promotion firm, to pay writers to publish articles about Lion on investment websites as well as to coordinate the distribution of articles to thousands of electronic mailboxes. Singh actively participated in Lidingo’s promotional work for Lion and understood that Lidingo was using writers who would not disclose that Lion was indirectly compensating them for their publications.”  Following this news, shares of Lion Biotechnologies fell $0.20 per share, or over 3%, to close at $6.35 per share on April 10, 2017.

The complaint alleges that throughout the Class Period the defendants made false and/or misleading statements and/or failed to disclose that (1) Lion Biotechnologies, through its former CEO Manish Singh, engaged in a scheme to mislead investors by commissioning over 10 internet publications and 20 widely distributed emails promoting Lion Biotechnologies to potential investors that purported to be independent from the company when, in fact, they were paid promotions; (2) former CEO Singh engaged a notorious stock promotion firm to pay writers to publish articles about Lion Biotechnologies on investment websites as well as to coordinate the distribution of articles to thousands of electronic mailboxes; (3) former CEO Singh actively participated in the promotional work for Lion Biotechnologies and understood that the promotion firm was using writers who would not disclose that Lion Biotechnologies was indirectly compensating them for their publications; and (4) as a result, defendants’ public statements were materially false and misleading at all relevant times.

If you are a member of the class described above, you may no later than June 13, 2017 move the Court to serve as lead plaintiff of the class, if you so choose. 


A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation.  In order to be appointed lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class.  Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Any member of the purported class may move the court to serve as a lead plaintiff through counsel of their choice, or may choose to do nothing and remain an inactive class member.

Kessler Topaz Meltzer & Check, LLP has not filed a complaint in this matter.  If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check, LLP toll free at 1-888-299-7706 or 1-610-667-7706, or via e-mail at info@ktmc.com.

CONTACT:
Kessler Topaz Meltzer & Check, LLP
James Maro, Esq. or Adrienne Bell, Esq.
280 King of Prussia Road
Radnor, PA 19087 1-888-299-7706 (toll free) or 1-610-667-7706
Or by e-mail at info@ktmc.com

Please complete this form and list your purchase and sale transaction(s) for Lion Biotechnologies, Inc. (“Lion Biotechnologies”) (Nasdaq: LBIO) securities between November 14, 2013 and April 10, 2017, inclusive (the “Class Period”):

Information Sheet
* Denotes required field
Acquisitions
Date Aquired
Number of Shares Acquired
Acquisition Price Per Share
Sales
Date Sold
Number of Shares Sold
Selling Price Per Share
Did you purchase shares of Lion Biotechnologies, Inc. prior to the class period?
Are you a current or former employee of Lion Biotechnologies, Inc.?
The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kessler Topaz or you to file a lead plaintiff motion in this matter. Any information you submit will be maintained as confidential. If Kessler Topaz, in its sole discretion, believes that you might be an appropriate lead plaintiff candidate, Kessler Topaz will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases.
How did you hear about this case?
Sign Up for Monthly Update: